Information Provided By:
Fly News Breaks for May 21, 2018
PRTA
May 21, 2018 | 05:05 EDT
Barclays analyst Geoffrey Meacham downgraded Prothena to Underweight and cut his price target for the shares to $12 from $14. The analyst sees limited value creating pipeline events in the near-term after the company discontinued development of NEOD001, an investigational antibody that was being evaluated for the treatment of AL amyloidosis. He believes it remains too early to assign much value to PRX002 in Parkinson's or PRX004 in ATTR amyloidosis.
News For PRTA From the Last 2 Days
There are no results for your query PRTA